• Business
  • Published 2013

Regulating Pharmaceutical Prices in the European Union

@inproceedings{Csizmazia2013RegulatingPP,
  title={Regulating Pharmaceutical Prices in the European Union},
  author={Roland Attila Csizmazia},
  year={2013}
}
This case study aims to provide a better understanding of the necessity for regulation in the market for pharmaceuticals and to reveal the impacts of parallel trades in the European Union and how they may affect markets in the future. The pharmaceutical industry up to now has largely been regulated. Although the EU is a single market, it still has variable prices for pharmaceuticals. Consequently, the price gap and other EU-specific factors have created a great environment for parallel trades… CONTINUE READING

Figures from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Challenges and Opportunities in the Chinese Herbal Drug Industry

  • L. Zhang, A. L. Demain
  • Natural Products : Drug Discovery and Therapeutic Medicine
  • 2005

Fakes!, Businessweek, 6 February, http://www.businessweek.com/stories/2005-02-06/fakes

  • F. Balfour, C. Matlack, +6 authors D. Brady
  • International Journal of Health Care Finance and Economics
  • 2005
VIEW 1 EXCERPT

Parallel Trade in the EU and US pharmaceutical markets

  • A. Wearing, I. Kirby, M. Van Kerckhove
  • 2004
VIEW 2 EXCERPTS

Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents

VIEW 1 EXCERPT

Patients’ health or company profits? The commercialisation of academic research

VIEW 1 EXCERPT